AGPAT2 and steatosis: It is reported that well-established lipodystrophy mouse models, such as Agpat2 disrupted mice and A-ZIP/F transgenic mice, develop severe lipodystrophy along with an elevation of a hepatic pool of triglycerides and upregulated hepatic de novo lipogenesis [34,35], suggesting that steatosis observed in lipodystrophy is complex, and hepatic de novo lipogenesis is, at least partially, one of the metabolic factors that contribute to steatosis.